I-SENS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 02:08 am EST
Share
i-SENS, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 68,513.87 million compared to KRW 59,009.32 million a year ago. Net income was KRW 2,003.19 million compared to KRW 6,984.09 million a year ago. Basic earnings per share from continuing operations was KRW 73 compared to KRW 257 a year ago. Diluted earnings per share from continuing operations was KRW 72.5 compared to KRW 256.5 a year ago. Basic earnings per share was KRW 73 compared to KRW 257 a year ago. Diluted earnings per share was KRW 72.5 compared to KRW 256.5 a year ago.
For the nine months, sales was KRW 2,438.75 million compared to KRW 1,455.14 million a year ago. Net income was KRW 17,420.96 million compared to KRW 22,793.64 million a year ago. Basic earnings per share from continuing operations was KRW 635 compared to KRW 838.5 a year ago. Diluted earnings per share from continuing operations was KRW 634 compared to KRW 836.5 a year ago. Basic earnings per share was KRW 635 compared to KRW 838.5 a year ago. Diluted earnings per share was KRW 634 compared to KRW 836.5 a year ago.
i-SENS, Inc. is a Korea-based company mainly engaged in the manufacture and sale of biosensors. The Companyâs products consist of blood glucose monitoring systems, including blood glucose monitors, blood glucose meters, glucose monitors, blood glucose meter kits and blood sugar meters under the brand names of CareSens, MedTrust, BGStar, Barozen and others; electrolyte analyzers and cartridges; immunosensors, as well as other related accessories, such as connectors, lancets, blood glucose data management software and lancing devices, among others. The Company distributes its products within domestic market and to overseas markets including Japan, Europe, the United States and others.
I-SENS, INC. 
